Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.060 -0.100 (-8.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
Where Caribou Biosciences Stands With Analysts
Via Benzinga
2 Stocks I'm Buying on the Dip This Week
Caribou Biosciences and AT&T screen as incredible bargains for patient investors. 
Via The Motley Fool
2 Magnificient Growth Stocks to Buy in July
These two growth stocks might be incredibly undervalued right now. 
Via The Motley Fool
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
Early-stage biotechs almost never warrant this level of enthusiasm. 
Via The Motley Fool
NXP Semiconductors To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Wednesday
HC Wainwright & Co. cut the price target for Caribou Biosciences, Inc. (NASDAQ: CRBU) from $25 to $23. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Caribou Biosciences shares fell... 
Via Benzinga
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
Simplifying the cell therapy manufacturing process could be worth a lot of money. 
Via The Motley Fool
Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years
It's still early going, but this small biotech shows great promise. 
Via The Motley Fool
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future. 
Via The Motley Fool
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement. 
Via Benzinga
Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M
Caribou Biosciences Inc (NASDAQ: CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Proposed Public Offering of Common Stock
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Pfizer Just Invested $25 million In This Biotech
Pfizer's investment propels Caribou Biosciences' stock and fuels optimism for its lead candidates: CB-010 and CB-011, both currently in phase 1 trials. 
Via MarketBeat
Benzinga's Stock Whisper Index: 5 Tickers Investors Secretly Monitor But Don't Talk About... Yet
Investors are on the hunt for undervalued, under followed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
Nasdaq Drops Over 100 Points; Genius Sports Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday. The Dow traded down 1.09% to 33,913.56 while the NASDAQ fell 0.96% to 13,659.77. The... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; ISM Services PMI Surges In June
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Thursday. The Dow traded down 1.38% to 33,814.23 while the NASDAQ fell 1.37% to 13,602.19. The S&P 500,... 
Via Benzinga
Why Shares of Caribou Biosciences Are Skyrocketing Today
The company's shares spiked after Pfizer bought $25 million of Caribou stock. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.